## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($102.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. Abivax (NASDAQ:ABVX) Downgraded by Wall Street Zen to "Sell"**
- Source: MarketBeat | 20251213T060915 | Somewhat-Bearish | Relevance: 100%
- Wall Street Zen downgraded Abivax (NASDAQ:ABVX) from a "hold" to a "sell" rating on Saturday. Despite this, other analysts maintain a "Moderate Buy" consensus with a target price of $123. Abivax, a clinical-stage biotech, is advancing its lead drug obefazimod for ulcerative colitis.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.2% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 2.8% to 0.5% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 (-4.5%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 2.35x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.54% (CS: 31) | Neutral |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 2.352x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $117.91
- **Stop Loss:** $102.73 (12.9% risk)
- **Target:** $133.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $9,314.89
- **Portfolio %:** 9.31%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*